NASDAQ:CHRS - Coherus BioSciences Stock Price, Price Target & More

$11.65 +0.20 (+1.75 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$11.45
Today's Range$11.35 - $11.90
52-Week Range$8.05 - $24.70
Volume421,070 shs
Average Volume735,144 shs
Market Capitalization$709.82 million
P/E Ratio-2.59
Dividend YieldN/A
Beta3.4

About Coherus BioSciences (NASDAQ:CHRS)

Coherus BioSciences logoCoherus BioSciences, Inc., a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis. It is also developing a pipeline of products in therapeutic areas, such as oncology, immunology, and ophthalmology comprising CHS-3351, a ranibizumab biosimilar; and CHS-2020, an aflibercept biosimilar, as well as CHS-131, a small molecule for multiple sclerosis. Coherus BioSciences, Inc. has license agreement with Selexis SA and Genentech, Inc. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Receive CHRS News and Ratings via Email

Sign-up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CHRS
CUSIPN/A
Phone650-649-3530

Debt

Debt-to-Equity Ratio3.33%
Current Ratio5.12%
Quick Ratio5.12%

Price-To-Earnings

Trailing P/E Ratio-2.59
Forward P/E Ratio-3.76
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.56 million
Price / Sales449.20
Cash FlowN/A
Price / CashN/A
Book Value$0.51 per share
Price / Book22.84

Profitability

EPS (Most Recent Fiscal Year)($4.48)
Net Income$-238,170,000.00
Net MarginsN/A
Return on Equity-493.03%
Return on Assets-126.67%

Miscellaneous

Employees122
Outstanding Shares60,150,000

How to Become a New Pot Stock Millionaire

Coherus BioSciences (NASDAQ:CHRS) Frequently Asked Questions

What is Coherus BioSciences' stock symbol?

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences (NASDAQ:CHRS) announced its quarterly earnings results on Thursday, March, 8th. The biotechnology company reported ($0.84) earnings per share for the quarter, beating analysts' consensus estimates of ($0.86) by $0.02. View Coherus BioSciences' Earnings History.

When is Coherus BioSciences' next earnings date?

Coherus BioSciences is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Coherus BioSciences.

What price target have analysts set for CHRS?

8 brokerages have issued twelve-month price targets for Coherus BioSciences' shares. Their predictions range from $15.00 to $46.00. On average, they expect Coherus BioSciences' share price to reach $31.6250 in the next twelve months. View Analyst Ratings for Coherus BioSciences.

What are Wall Street analysts saying about Coherus BioSciences stock?

Here are some recent quotes from research analysts about Coherus BioSciences stock:
  • 1. According to Zacks Investment Research, "Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California. " (1/9/2018)
  • 2. Maxim Group analysts commented, "The challenge for biosimilar makers of humira is not similar efficacy, it’s winning the IP battle with AbbVie. Coherus, in our view, was ideally positioned to win the biosimilar race as it was founded with a focus on IP." (9/8/2017)

Who are some of Coherus BioSciences' key competitors?

Who are Coherus BioSciences' key executives?

Coherus BioSciences' management team includes the folowing people:
  • Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 63)
  • Dr. Jean-Frédéric Viret, CFO & Principal Accounting Officer (Age 52)
  • Dr. Peter K. Watler Ph.D., Chief Technical Officer (Age 56)
  • Dr. Alan C. Herman, Chief Scientific Officer (Age 70)
  • Dr. Barbara K. Finck M.D., Chief Medical Officer (Age 71)

Has Coherus BioSciences been receiving favorable news coverage?

Media stories about CHRS stock have been trending somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Coherus BioSciences earned a news impact score of 0.14 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 45.49 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Coherus BioSciences?

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Coherus BioSciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $11.65.

How big of a company is Coherus BioSciences?

Coherus BioSciences has a market capitalization of $709.82 million and generates $1.56 million in revenue each year. The biotechnology company earns $-238,170,000.00 in net income (profit) each year or ($4.48) on an earnings per share basis. Coherus BioSciences employs 122 workers across the globe.

How can I contact Coherus BioSciences?

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]


MarketBeat Community Rating for Coherus BioSciences (CHRS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  194 (Vote Outperform)
Underperform Votes:  171 (Vote Underperform)
Total Votes:  365
MarketBeat's community ratings are surveys of what our community members think about Coherus BioSciences and other stocks. Vote "Outperform" if you believe CHRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHRS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Coherus BioSciences (NASDAQ:CHRS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Coherus BioSciences in the last 12 months. Their average twelve-month price target is $31.6250, suggesting that the stock has a possible upside of 171.46%. The high price target for CHRS is $46.00 and the low price target for CHRS is $15.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $31.6250$31.6250$32.00$34.00
Price Target Upside: 171.46% upside166.88% upside161.22% upside164.59% upside

Coherus BioSciences (NASDAQ:CHRS) Consensus Price Target History

Price Target History for Coherus BioSciences (NASDAQ:CHRS)

Coherus BioSciences (NASDAQ:CHRS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/9/2018CitigroupBoost Price TargetBuy -> Buy$23.00 -> $25.00LowView Rating Details
3/9/2018Maxim GroupReiterated RatingBuy -> Buy$20.00 -> $15.00HighView Rating Details
9/27/2017Credit Suisse GroupReiterated RatingOutperform$24.00 -> $17.00LowView Rating Details
9/8/2017CowenReiterated RatingOutperform$45.00LowView Rating Details
8/8/2017JPMorgan ChaseReiterated RatingOverweight -> Overweight$32.00 -> $25.00LowView Rating Details
6/13/2017BMO Capital MarketsLower Price TargetOutperform$54.00 -> $43.00HighView Rating Details
6/13/2017Robert W. BairdLower Price TargetOutperform$40.00 -> $37.00HighView Rating Details
5/21/2017BarclaysReiterated RatingOverweight$46.00HighView Rating Details
11/25/2016Standpoint ResearchInitiated CoverageBuy$40.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Coherus BioSciences (NASDAQ:CHRS) Earnings History and Estimates Chart

Earnings by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Coherus BioSciences (NASDAQ:CHRS) Earnings Estimates

Current Year EPS Consensus Estimate: $-3.1 EPS
Next Year EPS Consensus Estimate: $-1.67 EPS

Coherus BioSciences (NASDAQ CHRS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018N/AView Earnings Details
3/8/2018Q4 2017($0.8620)($0.84)ViewListenView Earnings Details
11/6/2017Q3 2017($0.8320)($1.09)ViewN/AView Earnings Details
8/7/2017Q2 2017($1.29)($1.08)$1.40 millionViewListenView Earnings Details
5/8/2017Q1 2017($1.54)($1.54)$0.16 millionViewListenView Earnings Details
3/13/2017Q4 2016($1.11)($1.71)$10.00 million$0.84 millionViewListenView Earnings Details
11/9/2016Q3 2016($1.5620)$1.67$7.20 million$162.80 millionViewListenView Earnings Details
8/9/2016Q2($1.32)($1.72)$6.87 million$14.07 millionViewListenView Earnings Details
5/9/2016Q1($1.42)($1.67)$12.36 millionViewListenView Earnings Details
2/29/2016Q4($1.74)($1.35)$8.63 million$10.20 millionViewListenView Earnings Details
11/9/2015Q3($1.86)$16.10 million$7.20 millionViewListenView Earnings Details
8/10/2015Q215($1.56)$488.15 million$6.87 millionViewListenView Earnings Details
5/11/2015Q115($1.22)$488.15 million$5.81 millionViewListenView Earnings Details
3/23/2015Q414($0.46)($1.47)$6.50 millionViewListenView Earnings Details
12/15/2014Q212($1.79)$16.10 millionViewN/AView Earnings Details
3/27/2012($0.02)($0.06)ViewN/AView Earnings Details
12/1/2011($0.09)($0.08)ViewN/AView Earnings Details
9/1/2011$0.01($0.01)ViewN/AView Earnings Details
6/2/2011$0.12$0.17ViewN/AView Earnings Details
3/24/2011($0.19)($0.08)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Coherus BioSciences (NASDAQ:CHRS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Coherus BioSciences (NASDAQ CHRS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 19.57%
Institutional Ownership Percentage: 82.22%
Insider Trading History for Coherus BioSciences (NASDAQ:CHRS)
Insider Trading History for Coherus BioSciences (NASDAQ:CHRS)

Coherus BioSciences (NASDAQ CHRS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/8/2017Alan C HermanInsiderSell17,535$15.02$263,375.7049,651View SEC Filing  
7/5/2017Alan C HermanInsiderSell600$15.00$9,000.0067,186View SEC Filing  
4/3/2017Alan C HermanInsiderSell11,333$20.73$234,933.0990,452View SEC Filing  
1/25/2017Jean-Frederic ViretCFOSell3,900$27.00$105,300.006,892View SEC Filing  
12/16/2016Jean-Frederic ViretCFOSell3,900$28.30$110,370.006,225View SEC Filing  
12/8/2016Mats WahlstromDirectorSell53,583$27.52$1,474,604.16View SEC Filing  
12/1/2016Alan C HermanInsiderSell11,333$27.40$310,524.20143,917View SEC Filing  
10/21/2016Jean-Frederic ViretCFOSell3,900$30.62$119,418.006,225View SEC Filing  
10/3/2016Alan C HermanInsiderSell11,333$25.69$291,144.77161,687View SEC Filing  
9/26/2016Jean-Frederic ViretCFOSell3,900$29.88$116,532.006,225View SEC Filing  
9/21/2016Dennis M LanfearInsiderSell4,060$31.75$128,905.0071,635View SEC Filing  
9/16/2016Dennis M LanfearInsiderSell2,900$31.79$92,191.0071,635View SEC Filing  
8/8/2016Fmr LlcInsiderSell100,000$29.86$2,986,000.00View SEC Filing  
8/5/2016Fmr LlcInsiderSell48,600$28.48$1,384,128.00View SEC Filing  
8/1/2016Alan C HermanInsiderSell11,333$25.54$289,444.82186,782View SEC Filing  
7/21/2016Peter K WatlerInsiderSell3,991$26.13$104,284.833,991View SEC Filing  
7/20/2016Peter K WatlerInsiderSell73,741$25.02$1,844,999.8250,000View SEC Filing  
7/11/2016Peter K WatlerInsiderSell43,495$20.02$870,769.90View SEC Filing  
7/1/2016Alan C HermanInsiderSell4,250$16.89$71,782.50198,115View SEC Filing  
6/1/2016Alan C HermanInsiderSell4,250$18.67$79,347.50202,365View SEC Filing  
5/17/2016Peter K WatlerInsiderSell12,000$20.00$240,000.00View SEC Filing  
5/2/2016Alan C HermanInsiderSell4,250$19.20$81,600.00207,167View SEC Filing  
2/5/2016Alan C HermanInsiderSell2,000$15.02$30,040.00221,615View SEC Filing  
12/1/2015Alan C. HermaninsiderSell11,333$29.49$334,210.17211,865View SEC Filing  
11/13/2015Christos RichardsDirectorSell15,000$27.49$412,350.0063,836View SEC Filing  
11/2/2015Alan C. HermaninsiderSell18,416$28.71$528,723.36214,699View SEC Filing  
10/1/2015Alan C. HermaninsiderSell4,250$18.98$80,665.00214,699View SEC Filing  
9/1/2015Alan C. HermaninsiderSell11,333$27.39$310,410.87214,699View SEC Filing  
8/18/2015Mats WahlstromDirectorSell6,373$33.50$213,495.50View SEC Filing  
8/17/2015Mats WahlstromDirectorSell8,028$33.91$272,229.48View SEC Filing  
8/14/2015Mats WahlstromDirectorSell116,554$34.24$3,990,808.96View SEC Filing  
6/15/2015August J TroendleDirectorSell250,000$26.68$6,670,000.00View SEC Filing  
11/12/2014Eli & Co LillyInsiderBuy164,963$13.50$2,227,000.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Coherus BioSciences (NASDAQ CHRS) News Headlines

Source:
DateHeadline
Reviewing Curis (CRIS) and Coherus BioSciences (CHRS)Reviewing Curis (CRIS) and Coherus BioSciences (CHRS)
www.americanbankingnews.com - April 25 at 1:38 PM
Coherus BioSciences to Report First Quarter 2018 Financial Results on May 10th  Coherus BioSciences to Report First Quarter 2018 Financial Results on May 10th  
finance.yahoo.com - April 24 at 9:10 AM
Coherus BioSciences (CHRS) Downgraded to Strong Sell at ValuEngineCoherus BioSciences (CHRS) Downgraded to Strong Sell at ValuEngine
www.americanbankingnews.com - April 21 at 8:42 AM
Coherus BioSciences (CHRS) Expected to Post Earnings of -$0.84 Per ShareCoherus BioSciences (CHRS) Expected to Post Earnings of -$0.84 Per Share
www.americanbankingnews.com - April 21 at 5:12 AM
JPMorgan Chase Reiterates "Overweight" Rating for Coherus BioSciences (CHRS)JPMorgan Chase Reiterates "Overweight" Rating for Coherus BioSciences (CHRS)
www.americanbankingnews.com - April 12 at 7:57 PM
Coherus BioSciences (CHRS) Rating Increased to Sell at ValuEngineCoherus BioSciences (CHRS) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - April 12 at 10:53 AM
Coherus BioSciences (CHRS) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowCoherus BioSciences (CHRS) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 4:39 PM
Coherus BioSciences (CHRS) Downgraded to Sell at Zacks Investment ResearchCoherus BioSciences (CHRS) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 7 at 3:53 PM
Coherus Biosciences Inc (CHRS) Receives Average Recommendation of "Buy" from AnalystsCoherus Biosciences Inc (CHRS) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 5 at 1:44 PM
Coherus Biosciences (CHRS) Rating Lowered to Strong Sell at ValuEngineCoherus Biosciences (CHRS) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - April 4 at 6:22 PM
Coherus BioSciences Management to Present at the HC Wainwright Annual Global Life Sciences Conference in Monte ...Coherus BioSciences Management to Present at the HC Wainwright Annual Global Life Sciences Conference in Monte ...
globenewswire.com - April 4 at 4:44 PM
 Analysts Expect Coherus Biosciences Inc (CHRS) Will Post Earnings of -$0.84 Per Share Analysts Expect Coherus Biosciences Inc (CHRS) Will Post Earnings of -$0.84 Per Share
www.americanbankingnews.com - April 4 at 5:10 AM
Coherus Biosciences (CHRS) Receives "Buy" Rating from CitigroupCoherus Biosciences (CHRS) Receives "Buy" Rating from Citigroup
www.americanbankingnews.com - April 1 at 3:10 PM
Form 8-K Coherus BioSciences, For: Mar 26Form 8-K Coherus BioSciences, For: Mar 26
www.streetinsider.com - March 27 at 4:46 PM
Coherus Biosciences (CHRS) Raised to Hold at BidaskClubCoherus Biosciences (CHRS) Raised to Hold at BidaskClub
www.americanbankingnews.com - March 24 at 8:23 PM
Coherus Biosciences Inc (CHRS) Expected to Announce Earnings of -$0.84 Per ShareCoherus Biosciences Inc (CHRS) Expected to Announce Earnings of -$0.84 Per Share
www.americanbankingnews.com - March 18 at 3:10 AM
Coherus BioSciences Announces New Employment Inducement GrantsCoherus BioSciences Announces New Employment Inducement Grants
finance.yahoo.com - March 13 at 4:59 PM
Coherus Biosciences Inc (CHRS) Given Consensus Rating of "Buy" by BrokeragesCoherus Biosciences Inc (CHRS) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 11 at 12:48 PM
Maxim Group Analysts Give Coherus Biosciences (CHRS) a $15.00 Price TargetMaxim Group Analysts Give Coherus Biosciences (CHRS) a $15.00 Price Target
www.americanbankingnews.com - March 10 at 5:08 PM
Coherus Biosciences (CHRS) Price Target Increased to $25.00 by Analysts at CitigroupCoherus Biosciences (CHRS) Price Target Increased to $25.00 by Analysts at Citigroup
www.americanbankingnews.com - March 9 at 9:40 PM
How This Small-Cap Biotech Plans To Chip Away At Amgen's Biggest DrugsHow This Small-Cap Biotech Plans To Chip Away At Amgen's Biggest Drugs
finance.yahoo.com - March 9 at 4:55 PM
Why Coherus Biosciences Is Skyrocketing TodayWhy Coherus Biosciences Is Skyrocketing Today
finance.yahoo.com - March 9 at 4:55 PM
Why II-VI, Coherus Biosciences, and El Pollo Loco Holdings Jumped TodayWhy II-VI, Coherus Biosciences, and El Pollo Loco Holdings Jumped Today
finance.yahoo.com - March 9 at 4:55 PM
Coherus Biosciences (CHRS) Posts  Earnings Results, Beats Expectations By $0.02 EPSCoherus Biosciences (CHRS) Posts Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - March 9 at 2:03 PM
Coherus BioSciences Reports Fourth Quarter and Full Year 2017 Financial ResultsCoherus BioSciences Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 8 at 4:46 PM
Coherus BioSciences, Inc. to Host Earnings CallCoherus BioSciences, Inc. to Host Earnings Call
finance.yahoo.com - March 8 at 4:46 PM
Coherus Biosciences (CHRS) Set to Announce Earnings on MondayCoherus Biosciences (CHRS) Set to Announce Earnings on Monday
www.americanbankingnews.com - March 5 at 2:16 AM
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March - GlobeNewswire (press release)Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March - GlobeNewswire (press release)
globenewswire.com - March 3 at 4:37 PM
Amgen (AMGN) Gets CHMP Nod to Expand EU Label of NeulastaAmgen (AMGN) Gets CHMP Nod to Expand EU Label of Neulasta
www.zacks.com - March 1 at 9:24 AM
Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in MarchCoherus BioSciences Management to Present at Two Investor Healthcare Conferences in March
finance.yahoo.com - March 1 at 9:24 AM
Coherus Biosciences Inc (CHRS) Expected to Announce Earnings of -$0.90 Per ShareCoherus Biosciences Inc (CHRS) Expected to Announce Earnings of -$0.90 Per Share
www.americanbankingnews.com - March 1 at 1:08 AM
Coherus Biosciences Inc (CHRS) Holdings Lifted by State of Wisconsin Investment BoardCoherus Biosciences Inc (CHRS) Holdings Lifted by State of Wisconsin Investment Board
www.americanbankingnews.com - February 28 at 5:34 PM
Brown Advisory Inc. Has $5.57 Million Holdings in Coherus Biosciences Inc (CHRS)Brown Advisory Inc. Has $5.57 Million Holdings in Coherus Biosciences Inc (CHRS)
www.americanbankingnews.com - February 28 at 5:14 AM
Coherus BioSciences to Report Fourth Quarter and Full Year 2017 Financial Results on March 8thCoherus BioSciences to Report Fourth Quarter and Full Year 2017 Financial Results on March 8th
finance.yahoo.com - February 27 at 9:52 AM
Analyzing Coherus Biosciences (CHRS) & Cidara Therapeutics (CDTX)Analyzing Coherus Biosciences (CHRS) & Cidara Therapeutics (CDTX)
www.americanbankingnews.com - February 17 at 1:16 AM
 Analysts Expect Coherus Biosciences Inc (CHRS) Will Post Earnings of -$0.90 Per Share Analysts Expect Coherus Biosciences Inc (CHRS) Will Post Earnings of -$0.90 Per Share
www.americanbankingnews.com - February 12 at 10:46 AM
AbSci Appoints Alan Herman, PhD to Scientific Advisory BoardAbSci Appoints Alan Herman, PhD to Scientific Advisory Board
finance.yahoo.com - February 5 at 3:24 PM
BidaskClub Lowers Coherus Biosciences (CHRS) to SellBidaskClub Lowers Coherus Biosciences (CHRS) to Sell
www.americanbankingnews.com - February 3 at 1:28 PM
Coherus Biosciences (CHRS) Downgraded by BidaskClub to "Hold"Coherus Biosciences (CHRS) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - January 28 at 10:00 AM
Coherus Biosciences Target of Unusually Large Options Trading (CHRS)Coherus Biosciences Target of Unusually Large Options Trading (CHRS)
www.americanbankingnews.com - January 25 at 1:52 AM
How a federal rule change helps this Peninsula drug company be masters of our own domain - San Francisco Business TimesHow a federal rule change helps this Peninsula drug company be 'masters of our own domain' - San Francisco Business Times
www.bizjournals.com - January 24 at 3:28 PM
Coherus Biosciences Inc (CHRS) Given Average Rating of "Buy" by AnalystsCoherus Biosciences Inc (CHRS) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - January 20 at 1:40 PM
Cramer reveals the biggest winners and losers from the JP...Cramer reveals the biggest winners and losers from the JP...
finance.yahoo.com - January 17 at 9:26 AM
Five Rules for This Market Beast: Cramers Mad Money Recap (Tues 1/16/18)Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)
finance.yahoo.com - January 17 at 9:26 AM
Winners & losers from JP Morgan Healthcare ConferenceWinners & losers from JP Morgan Healthcare Conference
finance.yahoo.com - January 17 at 9:26 AM
Coherus Biosciences (CHRS) Rating Increased to Buy at BidaskClubCoherus Biosciences (CHRS) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - January 13 at 5:38 PM
Coherus Biosciences (CHRS) Rating Lowered to Hold at Zacks Investment ResearchCoherus Biosciences (CHRS) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - January 9 at 7:12 PM
 Brokerages Expect Coherus Biosciences Inc (CHRS) Will Post Earnings of -$0.90 Per Share Brokerages Expect Coherus Biosciences Inc (CHRS) Will Post Earnings of -$0.90 Per Share
www.americanbankingnews.com - January 9 at 9:38 AM
Coherus BioSciences (CHRS) Receives Scheduling Notice from FDA Related to its CHS-1701 Pegfilgrastim Biosimilar ... - StreetInsider.comCoherus BioSciences (CHRS) Receives Scheduling Notice from FDA Related to its CHS-1701 Pegfilgrastim Biosimilar ... - StreetInsider.com
www.streetinsider.com - January 7 at 10:48 PM
Coherus BioSciences (CHRS) Receives Scheduling Notice from FDA Related to its CHS-1701 Pegfilgrastim Biosimilar Candidate Granting Type 2 MeetingCoherus BioSciences (CHRS) Receives Scheduling Notice from FDA Related to its CHS-1701 Pegfilgrastim Biosimilar Candidate Granting Type 2 Meeting
www.streetinsider.com - January 6 at 9:36 AM

SEC Filings

Coherus BioSciences (NASDAQ:CHRS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Coherus BioSciences (NASDAQ:CHRS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Coherus BioSciences (NASDAQ CHRS) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.